title: In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
abstract: Among the numerous clinical regimens used in combination chemotherapy, synergy is particularly marked in combinations containing cisplatin (CDDP). However, the clinical use of CDDP is sometimes limited due to its nephrotoxicity. Nedaplatin (NDP) is a second-generation platinum complex with reduced nephrotoxicity that may substitute for CDDP or even surpass it for use in combination with other drugs. We investigated the effects of combinations of NDP and other anticancer drugs on the growth of human small cell lung cancer cells (SBC-3) and non-small cell lung cancer cells (PC-14) using a three-dimensional analysis model. Among the combinations tested, the combination of NDP and irinotecan (CPT-11) showed the most marked synergistic interaction, and the synergism has also been observed against PC-14 cells. With regard to treatment schedule, a remarkable synergistic interaction was produced by concurrent exposure to NDP and CPT-11. On the other hand, sequential exposure to the two drugs led only to additivity. To analyze the interaction between the drugs, the effect of NDP on the 7-ethyl-1-hydroxy-CPT (the active form of CPT-11)-induced inhibitory effect on DNA topoisomerase I was examined. The topoisomerase I-inhibitory effect of 7-ethyl-1-hydroxy-CPT was enhanced 10-fold in the presence of NDP at microgram/milliliter concentrations. These biochemical interactions might be responsible for the synergistic interaction between NDP and CPT-11. These results suggest that the combination of NDP with CPT-11 may be clinically useful for the chemotherapy of lung cancer.
authors.affiliation: Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan. fkanzawa@gan2.res.ncc.go.jp
authors.forename: F
authors.initials: F
authors.lastname: Kanzawa
authors.forename: F
authors.initials: F
authors.lastname: Koizumi
authors.forename: Y
authors.initials: Y
authors.lastname: Koh
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: Y
authors.initials: Y
authors.lastname: Tatsumi
authors.forename: H
authors.initials: H
authors.lastname: Fukumoto
authors.forename: N
authors.initials: N
authors.lastname: Saijo
authors.forename: T
authors.initials: T
authors.lastname: Yoshioka
authors.forename: K
authors.initials: K
authors.lastname: Nishio
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002455:Cell Division / Q000187:drug effects; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms; D009944:Organoplatinum Compounds / Q000378:metabolism / Q000494:pharmacology*; D013844:Thiazoles / Q000378:metabolism; D045162:Thiazolidinediones; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009944:Organoplatinum Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D059004:Topoisomerase I Inhibitors; C114240:DN 108; D000077146:Irinotecan; C053989:nedaplatin; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin